Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, a global leader in mission-critical products and services, has opened a new distribution center in Dublin, Ireland, spanning nearly 69,000 square feet. This advanced facility enhances supply security for the biopharma market, creating 40 jobs and complementing the company's existing 76,000 square-foot presence in Ireland. This investment aligns with Avantor's strategy to expand its global footprint to meet increasing demand for essential biopharma products. The center will offer certified cGMP warehousing, clean rooms, and inventory solutions for improved customer service.
Avantor reported net sales of $1.86 billion, up 1.2% year-over-year, with core organic growth of 7.8%. The net income increased to $167 million, while adjusted EBITDA rose 6.9% to $384 million with a margin expansion to 20.7%. The operating cash flow was $258.3 million, and free cash flow was $219.3 million. Adjusted net leverage decreased to 3.6X. The company anticipates 2.5%-3.0% organic growth for the full year and updated adjusted EPS guidance to $1.38-$1.40.
Avantor, a global provider in life sciences and advanced technologies, will release its third quarter 2022 financial results on October 28, prior to market opening. A conference call will occur at 8:00 a.m. EDT on the same day to discuss these results. The company's extensive portfolio serves over 225,000 customer locations worldwide, supporting crucial research and development activities across numerous industries.
Avantor, Inc. (NYSE: AVTR) announced that its CEO, Michael Stubblefield, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 12, 2022, at 4:15 p.m. EDT. The session will be available via a live webcast on Avantor's investor website, with a replay accessible for 90 days post-event. Avantor is a global provider of critical products and services across various industries, serving over 225,000 customers globally.
Avantor reported second-quarter 2022 results with net sales of $1.91 billion, a 2.8% increase year-over-year. Core organic net sales grew 6.4%, primarily driven by a robust 20% growth in bioproduction. Net income rose to $187.4 million, and adjusted EBITDA increased 10.2% to $404.1 million. Diluted GAAP EPS stood at $0.28, while adjusted EPS was $0.37. Operating cash flow was $227.5 million, with free cash flow at $191.2 million. The company reduced adjusted net leverage to 3.9X, aligning with its long-term target range.
Avantor, Inc. (NYSE: AVTR) has appointed Kitty Sahin as EVP, Strategy and Corporate Development, effective immediately. With over 20 years of experience in corporate strategy and M&A, Sahin will lead Avantor’s strategic growth initiatives. CEO Michael Stubblefield emphasized the importance of her role in enhancing Avantor’s market position. Sahin previously held significant roles at companies like Novanta and Thermo Fisher. She expressed enthusiasm for contributing to Avantor's growth and success across business areas, benefiting all stakeholders.
Avantor, Inc. (NYSE: AVTR) will release its financial results for the second quarter of 2022 post-market on July 28, 2022. A conference call is scheduled for July 29, 2022, at 8:00 a.m. EDT for further discussions. The earnings press release and presentation will be available on Avantor's website. As a leading global provider in life sciences and advanced technologies, Avantor serves over 225,000 customer locations across more than 180 countries, highlighting its significant market presence. Investors are encouraged to tune in for insights into the company's performance.
Avantor (NYSE: AVTR) has announced a collaboration with GeminiBio to deliver custom hydrated solutions and cell culture media tailored for the biopharma industry. This partnership aims to enhance bioproduction workflows, particularly for emerging modalities like gene therapy, enabling faster product development from research through to commercialization. Avantor's strategic investments and acquisitions complement this initiative, demonstrating its commitment to optimizing customer processes and improving efficiency in biomanufacturing.
Avantor (NYSE: AVTR), a global leader in mission-critical products and services, announced that its President and CEO, Michael Stubblefield, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022, at 11:00 a.m. EDT. The event will take place in Rancho Palos Verde, California. Interested parties can access a live webcast on the company's investor section of their website, with a replay available for 90 days. Avantor serves over 225,000 customers across various industries, emphasizing innovation in life sciences and advanced technologies.
Summary not available.